Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study

BACKGROUND: Palbociclib combined with endocrine therapy has been approved as a front-line treatment for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer (ABC). A key challenge remains to uncover biomarkers to identify those patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Xiying, Zheng, Yabing, Cao, Wenming, Shen, Xiabo, Li, Guangliang, Chen, Junqing, Huang, Yuan, Huang, Ping, Shi, Lei, Ye, Weiwu, Zou, Weibin, Lou, Caijin, Lei, Lei, Huang, Jian, Chen, Zhanhong, Wang, Xiaojia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106007/
https://www.ncbi.nlm.nih.gov/pubmed/33987405
http://dx.doi.org/10.21037/atm-21-1340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106007/
https://www.ncbi.nlm.nih.gov/pubmed/33987405
http://dx.doi.org/10.21037/atm-21-1340

Ejemplares similares